Paris-based Sofinnova Partners raised €725 million for its second crossover fund targeting late-stage life sciences companies, the firm announced Monday.
Why it matters: The French firm hopes to boost commercialization prospects for European therapeutics and med tech, partner Kinam Hong tells Axios Pro.